Original
Estudio de las subfracciones lipoproteicas tras el tratamiento de simvastatina y ezetimiba, en monoterapia o combinado, en pacientes hiperlipidémicos
Study of lipoprotein subfractions following treatment with simvastatin and ezetimibe administred alone and in combination in hyperlipidemic patients
Antonio Hernández-Mijaresa,b,c,
, Celia Bañulsa,b,c, Lorena Belloda,c, Ana Jovera, Eva Soláa, Víctor M. Víctora,c,d, Milagros Rochaa,c,d
Autor para correspondencia
a Servicio de Endocrinología, Hospital Universitario Dr. Peset, Valencia, España
b Departamento de Medicina, Facultad de Medicina, Universidad de Valencia, Valencia, España
c Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España
d Centro de Investigación Biomédica en Red (CIBER) de enfermedades hepáticas y digestivas (CB06/04/0071), Universidad de Valencia, España
Leído
3861
Vecesse ha leído el artículo
633
Total PDF
3228
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 10 | 7 | 17 |
| 2025 11 | 62 | 8 | 70 |
| 2025 10 | 51 | 12 | 63 |
| 2025 9 | 37 | 22 | 59 |
| 2025 8 | 44 | 6 | 50 |
| 2025 7 | 33 | 5 | 38 |
| 2025 6 | 51 | 1 | 52 |
| 2025 5 | 29 | 4 | 33 |
| 2025 4 | 51 | 2 | 53 |
| 2025 3 | 35 | 3 | 38 |
| 2025 2 | 18 | 1 | 19 |
| 2025 1 | 27 | 1 | 28 |
| 2024 12 | 23 | 1 | 24 |
| 2024 11 | 16 | 1 | 17 |
| 2024 10 | 27 | 0 | 27 |
| 2024 9 | 16 | 4 | 20 |
| 2024 8 | 10 | 8 | 18 |
| 2024 7 | 14 | 3 | 17 |
| 2024 6 | 7 | 2 | 9 |
| 2024 5 | 16 | 6 | 22 |
| 2024 4 | 16 | 5 | 21 |
| 2024 3 | 17 | 10 | 27 |
| 2024 2 | 17 | 5 | 22 |
| 2024 1 | 31 | 5 | 36 |
| 2023 12 | 16 | 9 | 25 |
| 2023 11 | 19 | 10 | 29 |
| 2023 10 | 33 | 8 | 41 |
| 2023 9 | 23 | 8 | 31 |
| 2023 8 | 27 | 22 | 49 |
| 2023 7 | 11 | 4 | 15 |
| 2023 6 | 12 | 5 | 17 |
| 2023 5 | 18 | 3 | 21 |
| 2023 4 | 27 | 4 | 31 |
| 2023 3 | 23 | 2 | 25 |
| 2023 2 | 23 | 3 | 26 |
| 2022 1 | 14 | 9 | 23 |
| 2022 12 | 22 | 4 | 26 |
| 2022 11 | 23 | 7 | 30 |
| 2022 10 | 17 | 9 | 26 |
| 2022 9 | 19 | 8 | 27 |
| 2022 8 | 29 | 13 | 42 |
| 2022 7 | 22 | 4 | 26 |
| 2022 6 | 39 | 10 | 49 |
| 2022 5 | 28 | 7 | 35 |
| 2022 4 | 51 | 6 | 57 |
| 2022 3 | 84 | 5 | 89 |
| 2022 2 | 55 | 9 | 64 |
| 2018 4 | 8 | 2 | 10 |
| 2018 3 | 10 | 1 | 11 |
| 2018 2 | 16 | 3 | 19 |
| 2018 1 | 8 | 1 | 9 |
| 2017 12 | 19 | 0 | 19 |
| 2017 11 | 18 | 5 | 23 |
| 2017 10 | 19 | 4 | 23 |
| 2017 9 | 18 | 6 | 24 |
| 2017 8 | 21 | 4 | 25 |
| 2017 7 | 9 | 3 | 12 |
| 2017 6 | 15 | 20 | 35 |
| 2017 5 | 22 | 2 | 24 |
| 2017 4 | 28 | 3 | 31 |
| 2017 3 | 33 | 44 | 77 |
| 2017 2 | 23 | 3 | 26 |
| 2016 1 | 21 | 0 | 21 |
| 2016 12 | 27 | 6 | 33 |
| 2016 11 | 34 | 4 | 38 |
| 2016 10 | 54 | 6 | 60 |
| 2016 9 | 40 | 6 | 46 |
| 2016 8 | 30 | 5 | 35 |
| 2016 7 | 44 | 7 | 51 |
| 2016 6 | 28 | 12 | 40 |
| 2016 5 | 20 | 7 | 27 |
| 2016 4 | 24 | 11 | 35 |
| 2016 3 | 19 | 15 | 34 |
| 2016 2 | 17 | 9 | 26 |
| 2015 1 | 16 | 10 | 26 |
| 2015 12 | 14 | 8 | 22 |
| 2015 11 | 17 | 11 | 28 |
| 2015 10 | 32 | 16 | 48 |
| 2015 9 | 24 | 10 | 34 |
| 2015 8 | 21 | 4 | 25 |
| 2015 7 | 20 | 4 | 24 |
| 2015 6 | 14 | 0 | 14 |
| 2015 5 | 16 | 4 | 20 |
| 2015 4 | 15 | 6 | 21 |
| 2015 3 | 18 | 7 | 25 |
| 2015 2 | 7 | 3 | 10 |
| 2015 1 | 21 | 4 | 25 |
| 2014 12 | 34 | 3 | 37 |
| 2014 11 | 42 | 4 | 46 |
| 2014 10 | 42 | 2 | 44 |
| 2014 9 | 30 | 2 | 32 |
| 2014 8 | 20 | 3 | 23 |
| 2014 7 | 36 | 3 | 39 |
| 2014 6 | 25 | 1 | 26 |
| 2014 5 | 22 | 1 | 23 |
| 2014 4 | 31 | 3 | 34 |
| 2014 3 | 50 | 4 | 54 |
| 2014 2 | 47 | 4 | 51 |
| 2014 1 | 46 | 4 | 50 |
| 2013 12 | 67 | 1 | 68 |
| 2013 11 | 61 | 4 | 65 |
| 2013 10 | 57 | 5 | 62 |
| 2013 9 | 47 | 9 | 56 |
| 2013 8 | 50 | 11 | 61 |
| 2013 7 | 48 | 2 | 50 |
| 2013 6 | 10 | 0 | 10 |
| 2013 5 | 12 | 0 | 12 |
| 2013 4 | 17 | 0 | 17 |
| 2013 3 | 12 | 0 | 12 |
| 2013 2 | 3 | 0 | 3 |
| 2012 12 | 1 | 0 | 1 |
| 2012 11 | 3 | 0 | 3 |
| 2012 8 | 262 | 0 | 262 |
Mostrar todo